Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system

Histopathology

Volumn 70, Issue 2, 2017, Pages 253-263

  Schats, Kelly A ^a,b   Van Vré, Emily A ^a   De Schepper, Stefanie ^a   Boeckx, Carolien ^a   Schrijvers, Dorien M ^a   Waelput, Wim ^a,c   Fransen, Erik ^b   Vanden Bempt, Isabelle ^a   Neyns, Bart ^c   De Meester, Ingrid ^b   Kockx, Mark M ^a  

^a HistoGeneX NV   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

E1L3N; immunohistochemistry; Nanostring; PD L1; SP142

Indexed keywords

MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MELANOMA METASTASIS; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY ANALYSIS; VALIDITY; MELANOMA; PROCEDURES; VALIDATION STUDY;

ANTIGENS, CD274; BIOMARKERS, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; REPRODUCIBILITY OF RESULTS;

EID: 84990898947     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.13056     Document Type: Article

References (26)

1. Speiser DE, Utzschneider DT, Oberle SG, Munz C, Romero P, Zehn D. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat. Rev. Immunol. 2014; 14; 768–774.
2. Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015; 36; 265–276.
3. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012; 12; 252–264.
4. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012; 366; 2443–2454.
5. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012; 366; 2455–2465.
6. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015; 372; 2018–2028.
7. Rebelatto MC, Mistry A, Sabalos C et al. Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients. J. Clin. Oncol. 2015: 4736; Abstract 8033.
8. Lipson EJ, Vincent JG, Loyo M et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol. Res. 2013; 1; 54–63.
9. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515; 563–567.
10. Taube JM, Anders RA, Young GD et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 2012; 4; 127ra37.
11. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 2015; 14; 847–856.
12. Hansen AR, Siu LL. PD-L1 testing in cancer: challenges in companion diagnostic development. JAMA Oncol. 2016; 2; 15–16.
13. Cree IA, Booton R, Cane P et al. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology 2016; 69; 177–186.
14. Smith NR, Womack C. A matrix approach to guide IHC-based tissue biomarker development in oncology drug discovery. J. Pathol. 2014; 232; 190–198.
15. Velcheti V, Schalper KA, Carvajal DE et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab. Invest. 2014; 94; 107–116.
16. Joseph RW, Parasramka M, Eckel-Passow JE et al. Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma. Cancer Immunol. Res. 2013; 1; 378–385.
17. Massi D, Brusa D, Merelli B et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann. Oncol. 2014; 25; 2433–2442.
18. Darb-Esfahani S, Kunze CA, Kulbe H et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget 2016; 7; 1486–1499.
19. Veldman-Jones MH, Brant R, Rooney C et al. Evaluating robustness and sensitivity of the nanostring technologies nCounter platform to enable multiplexed gene expression analysis of clinical samples. Cancer Res. 2015; 75; 2587–2593.
20. Sunshine JC, Berry S, Esandrio J et al. Measurement of PD-L1 in melanoma: a quantitative antibody comparison. J. ImmunoTher. Cancer 2015; 3(Suppl. 2); P107.
21. McLaughlin J, Han G, Schalper KA et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016; 2; 46–54.
22. Madore J, Vilain RE, Menzies AM et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res. 2015; 28; 245–253.
23. Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S, Tsuta K. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer 2015; 88; 154–159.
24. McCarty KS Jr, Szabo E, Flowers JL et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res. 1986; 46; 4244s–4248s.
25. Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015; 75; 2139–2145.
26. ™ methodology. Exp. Rev. Precision Med. Drug Devel. 2016; 1; 9–24.